<DOC>
	<DOCNO>NCT02189174</DOCNO>
	<brief_summary>To estimate maximum tolerate dose ( MTD ) recommend dose phase II ( RP2D ) CLR457 investigate anti-tumor activity CLR457</brief_summary>
	<brief_title>Study CLR457 Administered Orally Adult Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Written informed consent must obtain prior screen procedure Phase I : Patients advanced/metastatic solid tumor , measurable nonmeasurable disease determine modified RECIST version 1.1 progress despite standard therapy intolerant standard therapy , standard therapy exists , tumor harbor one following : confirm PIK3CA mutation amplification , PTEN loss function , EGFR mutation , cMET activation and/or HER2 overexpression . Endometrial carcinoma select molecular status . Phase II : Patients advanced/metastatic solid tumor , least one measurable lesion determine modified RECIST version 1.1 , progress despite standard therapy intolerant standard therapy , standard therapy exists , fit one follow group : Group 1 : patient PIK3CA mutate amplified ER positive ( ER+ ) breast cancer ; Group 2 : patient endometrial carcinoma ( select molecular status ) ; Group 3 : patient solid tumor ( exception PIK3CA mutant/amplified ER+ breast cancer endometrial carcinoma ) harbor PIK3CA mutation amplification/any PTEN status ; Group 4 : patient solid tumor ( exception endometrial carcinoma ) harbor PTEN loss function/ PIK3CA wild type ; Group 5 : nonsmall cell lung cancer harbor cMET activation and/or EGFR mutation . Up 3 line chemotherapy allow advanced/metastatic setting . ECOG Performance Status ≤ 2 . Availability representative formalin fix paraffin embed tumor tissue sample . If archival tumor sample available , newly obtain tumor sample need submit instead . Brain metastasis unless treat neurologically stable Patient range laboratory value define : Hepatic renal function : Serum total Bilirubin ≥ 1.5 x ULN ( upper limit normal ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 2.5 x ULN For patient tumor involvement liver AST ALT &gt; 5 x ULN For patient Gilbert 's syndrome total bilirubin &gt; 2.5 x ULN Serum creatinine &gt; 1.5 x ULN and/or measure calculated creatinine clearance &lt; 75 % LLN ( low limit normal ) Bone marrow function : Platelets &lt; 100 x 109/L Hemoglobin ( Hgb ) &lt; 9 g/dL Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L Cardiac function : Clinically significant and/or uncontrolled heart disease congestive heart failure ( CHF ) require treatment ( NYH grade ≥2 ) , hypertension arrhythmia Left ventricular ejection fraction ( LVEF ) &lt; 45 % determine MUGA scan ECHO QTcF &gt; 480 msec screen ECG congenital long QT syndrome Acute myocardial infarction ( AMI ) unstable angina pectoris &lt; 3 month prior study entry Peripheral neuropathy CTCAE Grade ≥2 History pancreatitis grade Patients diabetes mellitus require insulin treatment and/or clinical sign Fasting Plasma Glucose ( FPG ) ≥ 140 mg/dL / 7.8 mmol/L Patients receive treatment medication know 1 ) strong inhibitor inducer CYP3A4/5 ; 2 ) CYP2C9 substrate narrow therapeutic index ; 3 ) QT prolong agent ; 4 ) proton pump inhibitor unless medication discontinue least week prior start treatment . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Solid tumor ,</keyword>
	<keyword>breast cancer ,</keyword>
	<keyword>lung cancer ,</keyword>
	<keyword>endometrial cancer</keyword>
</DOC>